Next Article in Journal
99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
Previous Article in Journal
Three-Dimensional Conformal Radiotherapy-Based or Intensity-Modulated Radiotherapy-Based Concurrent Chemoradiotherapy in Patients with Thoracic Esophageal Squamous Cell Carcinoma
Previous Article in Special Issue
LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential
Open AccessReview

Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors

CRCINA, INSERM, Université d’Angers, Université de Nantes, 44007 Nantes, France
Author to whom correspondence should be addressed.
Cancers 2019, 11(10), 1530;
Received: 7 August 2019 / Revised: 9 September 2019 / Accepted: 3 October 2019 / Published: 10 October 2019
(This article belongs to the Special Issue Epigenetic Dysregulation in Cancer: From Mechanism to Therapy)
Over recent decades, it has become clear that epigenetic abnormalities are involved in the hallmarks of cancer. Histone modifications, such as acetylation, play a crucial role in cancer development and progression, by regulating gene expression, such as for oncogenes or tumor suppressor genes. Therefore, histone deacetylase inhibitors (HDACi) have recently shown efficacy against both hematological and solid cancers. Designed to target histone deacetylases (HDAC), these drugs can modify the expression pattern of numerous genes including those coding for micro-RNAs (miRNA). miRNAs are small non-coding RNAs that regulate gene expression by targeting messenger RNA. Current research has found that miRNAs from a tumor can be investigated in the tumor itself, as well as in patient body fluids. In this review, we summarized current knowledge about HDAC and HDACi in several cancers, and described their impact on miRNA expression. We discuss briefly how circulating miRNAs may be used as biomarkers of HDACi response and used to investigate response to treatment. View Full-Text
Keywords: microRNA; HDAC inhibitors; exosome; cancer microRNA; HDAC inhibitors; exosome; cancer
Show Figures

Figure 1

MDPI and ACS Style

Autin, P.; Blanquart, C.; Fradin, D. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers 2019, 11, 1530.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop